MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience

    E. Pekkonen, J. Lyytinen, O. Lindström, L. Kylänpää, M. Udd (Helsinki, Finland)

    Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…
  • 2016 International Congress

    A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients

    K. Kieburtz, C.W. Olanow, Y. Cohen, S. Oren (Rochester, NY, USA)

    Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…
  • 2016 International Congress

    Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch

    N. Fixler, L. Reitblat, A. Wagner, S. Cohen, M. Afek, P. Bonato, J.F. Daneault, N. Golabchi, S. Moore, A. Patel, C. Cho, L. Bataille (Petach Tikva, Israel)

    Objective: To determine whether smartwatch sensor data correlates with clinician-measured Parkinson's disease symptoms. Background: Data collected with smartwatches could be used for long-term, continuous assessment…
  • 2016 International Congress

    Automated Telehealth Diagnostics for Remote Parkinson Monitoring

    D.A. Heldman, D.A. Harris, T. Felong, B. Goldberg, J.P. Giuffrida, E.R. Dorsey, M.A. Burack (Cleveland, OH, USA)

    Objective: To clinically assess and evaluate the impact of automated telehealth diagnostics on patients with Parkinson's disease (PD). Background: A single evaluation in a clinical…
  • 2016 International Congress

    Multidisciplinary Parkinson rehabilitation in the Netherlands: The effectiveness of points of Parkinson (POP)

    E.T. Steendam-Oldekamp, W.A.W.F. Rutgers, T. van Laar (Groningen, Netherlands)

    Objective: To analyze the effect of the POP rehab program for advanced PD patients on motor- and non-motor symptoms up to 2 years and determine…
  • 2016 International Congress

    Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study

    M. Senek, D. Nyholm (Uppsala, Sweden)

    Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…
  • 2016 International Congress

    Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa

    R. Shaltiel-Karyo, E. Zawoznik, I. Weinstock, M. Nemas, Y. Caraco, P.A. LeWitt, S. Oren, O. Yacoby-Zeevi (Rehovot, Israel)

    Objective: To characterize the peripheral pharmacokinetics and CNS metabolism of levodopa during continuous subcutaneous delivery of solubilized carbidopa. Background: Although many commercial levodopa formulations include…
  • 2016 International Congress

    Biseptol a new antiParkinsonian agent?

    K. Karpinska, V. Smolanka (Uzhgorod, Ukraine)

    Objective: To evaluate the possible effect of combined intake of levodopa/carbidopa and trimethoprim/sulfamethoxazole on the duration of ON/OFF periods in a PD patient. Background: Drug…
  • 2016 International Congress

    Quantitative assessment of advanced therapies in Parkinson’s disease using the Parkinson kinetigraph (PKG)

    R.L. Blaze, J. Tan, A.H. Evans (Parkville, Australia)

    Objective: Our aim was to establish whether objective measurements using the Parkinson's Kinetigraph can detect differences between patients undergoing different advanced therapy with either deep…
  • 2016 International Congress

    Effectiveness of Levodopa responsiveness of Blink reflex recovery: An objective method to differentiate Parkinsonian syndromes

    C. Gaddipati, M. Umaiorubahan, C.U. Velmurugendran, V. Shankar (Chennai, India)

    Objective: We attempted to find an objective tool by assessing the variability of levodopa induced change in the blink reflex recovery to differentiate Parkinsonian syndromes.…
  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley